QUHILL, F.; BEIDERBECK, A. Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema. Global and Regional Health Technology Assessment, [S. l.], v. 4, n. 1, p. 155–164, 2017. DOI: 10.33393/grhta.2017.391. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/391. Acesso em: 3 jul. 2024.